Here we demonstrate that normalization of neurobehavioral deficits in a mouse model of MPS II are associated with a reduction in GAG and Nf-L levels, suggesting a reduction in these biomarkers may reflect cognitive improvement with therapies that cross the BBB, such as ETV:IDS. The gene discussed is NEFL; the disease is mucopolysaccharidosis type 2.